

## t(3;11)(q26;p15)

### Clinics and Pathology

**Disease** [Chronic myelogenous leukaemia](#) with t(9;22)(q34;q11)

**Epidemiology** Only one case to date, a 64 year old male patient

**Prognosis** No data

### Cytogenetics

**Cytogenetics**  
**Morphological** Anomaly accompanying the [t\(9;22\)\(q34;q11\)](#)

### Genes involved and Proteins

**Note** The partner of EVI1 is yet unknown.

**Gene Name** [EVI1](#)

**Location** 3q26.2

**Protein** Transcription factor; EVI1 targets include:GATA2, [ZBTB16 /PLZF](#), ZFPM2/FOG2, [JNK](#) and the PI3K/AKT pathway. Role in cell cycle progression, likely to be cell-type dependant; antiapoptotic factor; involved in neuronal development organogenesis; role in hematopoietic differnsiation

### External links

**Other database** [t\(3;11\)\(q26;p15\)](#) [Mitelman database \(CGAP - NCBI\)](#)

**Other database** [t\(3;11\)\(q26;p15\)](#) [CancerChromosomes \(NCBI\)](#)

### To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:  
**you are welcome to submit a paper to our new [Case Report](#) section.**

### Bibliography

**EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.**

Poppe B, Dastugue N, Vandesomepele J, Cauwelier B, De Smet B, Yigit N, De Paepe A, Cervera J, Recher C, De Mas V, Hagemeyer A, Speleman F.

Genes Chromosomes Cancer 2006; 45: 349-356.

Medline [16342172](#)

**The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.**

Wieser R.

Gene 2007; 396: 346-357.

Medline [17507183](#)

### Contributor(s)

**Written** 05-2007 Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers; CHU Poitiers Hospital, F-86021 Poitiers, France

### Citation

*This paper should be referenced as such :*

**Huret JL** . t(3;11)(q26;p15). Atlas Genet Cytogenet Oncol Haematol. May 2007 .

URL : <http://AtlasGeneticsOncology.org/Anomalies/t0311q26p15ID1474.html>